论文部分内容阅读
近十年来已证实阿斯匹林(ASA)是一种强力的血小板聚集抑制剂。血栓形成虽取决于许多因素,但仅就抗血小板粘附和聚集性方面,临床上已确认ASA有预防缺血性脑血管病的作用。只是由于用药剂量大(1～1.5g/日)和付作用多,对其推广用药受到很大影响。近几年随着对药物作用机制及其生化代谢的研究,多数认为小剂量用药更为合理,大量临床资料也证实小剂量ASA的抗血小板聚集能力并不亚于甚至优于大剂量用药。本文仅就该药的剂量选择和预防缺血性脑血管病的研究进展综述如下。小剂量用药的理论基础血小板内的磷脂化花生四烯酸被磷脂酶
Aspirin (ASA) has been shown to be a potent inhibitor of platelet aggregation over the past decade. Although thrombus formation depends on many factors, the role of ASA in preventing ischemic cerebrovascular disease has been clinically confirmed with respect to anti-platelet adhesion and aggregation. Just because of the large dose (1 ~ 1.5g / day) and pay more, to promote its use of drugs has been greatly affected. In recent years, with the study of the mechanism of drug action and its biochemical metabolism, most consider that the use of small doses more reasonable, a large number of clinical data also confirmed that low-dose ASA anti-platelet aggregation and no less than even superior to large doses of medication. This article only on the drug dose selection and prevention of ischemic cerebrovascular disease research progress are summarized below. The rationale for small doses of medication Phospholipid arachidonic acid within platelets is phospholipase